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PLASMA RICH IN GROWTH FACTORS (PRGF-ENDORET) IN THE
TREATMENT OF SYMPTOMATIC KNEE OSTEOARTHRITIS:
A RANDOMIZED CLINICAL TRIAL
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01007 Vitoria (Spain)., Vitoria, Spain; 3Hosp. Donostia. Paseo Doctor
Begiristain 115. San Sebastián- Donostia (Spain)., San Sebastian, Spain;
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Purpose: This multicenter, double-blind, hyaluronic acid-controlled clin-
ical trial evaluated the efﬁcacy and safety of PRGF-Endoret, an autologous
biological therapy for regenerative purposes, as a treatment for knee pain
from osteoarthritis.
Methods: We randomly assigned 176 patients with symptomatic knee
osteoarthritis to receive inﬁltrations with PRGF-Endoret or with hyaluronic
acid (three injections on a weekly basis). The primary outcome measure
was a 50 percent decrease in knee pain from baseline to week 24. We also
assessed pain, stiffness, and physical function using theWOMAC Index; the
rate of response using the criteria of the OMERACT-OARSI; and safety.
Results: The mean age of the patients was 59.8 years, and 52 percent were
women. As compared with the rate of response to hyaluronic acid, the rate
of response to PRGF-Endoret was 14.1 percentage points higher (P¼0.044).
Regarding the secondary outcome measures, the rate of response to PRGF-Endoret was in all the cases higher, although no signiﬁcant differences
were reached. For patients with moderate to severe pain at baseline, the
rate of response to PRGF-Endoret was 26 percentage points higher
(P¼0.086) than the rate of response to hyaluronic acid, although no
signiﬁcant differences were reached. Adverse events were mild and evenly
distributed among the groups.
Conclusions:PRGF-Endoret has both a faster time to response and more
enduring beneﬁcial effect than hyaluronic acid. Treatment with PRGF-
Endoret resulted in clinically signiﬁcant reductions in knee pain, stiffness
and physical function, with mild adverse effects, in patients with knee
osteoarthritis. (ClinicalTrials.gov number, NCT00782197).
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A PROSPECTIVE, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND
FEASIBILITY STUDY TO EVALUATE THE SAFETY AND PERFORMANCE
OF HYDROS JOINT THERAPY AND HYDROS-TA JOINT THERAPY FOR
MANAGEMENT OF PAIN ASSOCIATED WITH OSTEOARTHRITIS IN THE
KNEE
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Purpose: Carbylan Osteoarthritis Research 1.0 (COR 1.0) was a prospective,
multicenter, randomized, double-blind feasibility study to evaluate the
safety and performance of Hydros Joint Therapy (Hydros) and Hydros-TA
Joint Therapy (Hydros-TA) in subjects with Kellgren&Lawrence grade 2 and
3 osteoarthritis (OA) of the knee.
Methods: A total of 98 subjects were enrolled, treated, and followed for six
months post-treatment. Subjects were randomized 1:1:1 to Hydros (PEG
cross linked HA without TA), Hydros-TA (PEG cross linked HA with TA), or
Synvisc-One Hylan G-F 20 (Synvisc-One).
Hydros is a bioresorbable hyaluronan-based hydrogel suspended in
a hyaluronan solution. Hydros-TA incorporates a low dose (10mg) corti-
costeroid, triamcinolone acetonide, suspended within the hyaluronan
hydrogel, and is designed to retain steroid locally in the joint.
All randomized subjects received one 6 mL intra-articular (IA) injection in
the treatment knee by an unblinded injecting physician. The treatment
knee was the knee that met the inclusion criteria on the Western Ontario
and McMaster Universities Osteoarthritis Index (WOMAC) A (pain)
subscale score (50-90mm on 100mm VAS). Subjects and evaluating
physicians who followed subjects post-treatment were blinded to
treatment.
Subjects were seen by a treatment-blinded evaluating physician for post-
treatment follow-up at 2 weeks, 6 weeks, 13 weeks, and 26 weeks.
Subjective symptom rating and physical assessment including the full
WOMAC questionnaire were obtained at screening and each follow-up
visit. Subject global assessment was obtained at 13 weeks and subject and
physician global assessments were obtained at 26 weeks. Adverse events
were solicited at all visits.
The primary efﬁcacy endpoint was the time-weighted change from base-
line in the WOMAC A (pain) subscale average score for the treatment knee
over 26 weeks. Differences between treatment were assessed using an
analysis of covariance (ANCOVA) model.
Results: For the primary outcome, Hydros demonstrated a 41.2mm
reduction, Hydros-TA demonstrated a 42.2mm reduction and Synvisc-One
demonstrated a 37.5mm reduction from baseline pain. These results rep-
resented an improvement of 3.7mm and 4.7mm over Synvisc-One for
Hydros and Hydros-TA respectively. Greater reductions in pain for Hydros-
TA vs Synvisc-One were observed at all timepoints over the course of the
study.
The percentage of subjects who responded favorably to the product (as
measured by the OMERACT-OARSI responder rate) was also higher in the
Hydros and Hydros-TA groups when compared to Synvisc-One. Hydros-
TA showed a trend towards a faster onset of pain relief compared to the
non-steroid containing products evaluated in the study. Hydros-TA
provided a 43.5mm mean reduction from baseline pain at the 2 week
time point compared to a mean reduction of 37.7mm and 32.3mm for
Synvisc-One and Hydros, respectively. In the Hydros-TA treatment group
